RESUMO
OBJECTIVE: The outbreak of hemolytic-uremic syndrome and diarrhea caused by Shiga toxin-producing Escherichia coli O104:H4 in Germany during May to July 2011 involved severe and characteristic neurologic manifestations with a strong female preponderance. Owing to these observations, we designed a series of experimental studies to evaluate the underlying mechanism of action of this clinical picture. METHODS: A magnetic resonance imaging and electroencephalographic study of patients was performed to evaluate the clinical picture in detail. Thereafter, combinations of different experimental settings, including electrophysiological and histological analyses, as well as calcium imaging in brain slices of rats, were conducted. RESULTS: We report on 7 female patients with neurologic symptoms and signs including bilateral thalamic lesions and encephalopathic changes indicative of a predominant involvement of the thalamus. Experimental studies in rats revealed an enhanced expression of the Shiga toxin receptor globotriaosylceramide on thalamic neurons in female rats as compared to other brain regions in the same rats and to male animals. Incubation of brain slices with Shiga toxin 2 evoked a strong membrane depolarization and intracellular calcium accumulation in neurons, associated with neuronal apoptosis, predominantly in the thalamic area. INTERPRETATION: These findings suggest that the direct cytotoxic effect of Shiga toxin 2 in the thalamus might contribute to the pathophysiology of neuronal complications in hemolytic-uremic syndrome.
Assuntos
Infecções por Escherichia coli/complicações , Doenças do Sistema Nervoso/etiologia , Doenças do Sistema Nervoso/patologia , Toxina Shiga II/toxicidade , Tálamo/patologia , Adulto , Idoso , Animais , Animais Recém-Nascidos , Apoptose/efeitos dos fármacos , Astrócitos/efeitos dos fármacos , Astrócitos/metabolismo , Cálcio/metabolismo , Eletroencefalografia , Infecções por Escherichia coli/líquido cefalorraquidiano , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Técnicas In Vitro , Imageamento por Ressonância Magnética , Potenciais da Membrana/efeitos dos fármacos , Doenças do Sistema Nervoso/líquido cefalorraquidiano , Neurônios/efeitos dos fármacos , Técnicas de Patch-Clamp , RNA Mensageiro/metabolismo , Ratos , Ratos Long-Evans , Caracteres Sexuais , Tálamo/fisiopatologia , Triexosilceramidas/metabolismo , Adulto JovemRESUMO
S100B is a predominantly astrocytic protein with dose-dependent cytotoxic and neurotrophic properties encoded on chromosome 21q22.3. Concentrations of S100B were measured in the cerebrospinal fluid (CSF) of 31 patients with Alzheimer's disease (AD), 36 patients with frontotemporal lobe dementia (FTLD) and 49 patients with other non-inflammatory neurological diseases. Additional CSF S100B concentrations were correlated with normalised brain volume measurements in AD and FTLD. CSF S100B was significantly higher in AD (Mean+/-standard deviation=0.4+/-0.2 ng/ml) and FTLD (0.42+/-0.19 ng/ml) patients when compared with control subjects (0.25+/-0.08, P<0.001). In patients with AD, S100B correlated negatively with normalised brain volume (R(S)=-0.53, P<0.001). No such correlation was found for FTLD patients. This study supports the concept that S100B is of pathological relevance for degeneration of the central nervous system in AD.
Assuntos
Doença de Alzheimer/líquido cefalorraquidiano , Encéfalo/patologia , Fatores de Crescimento Neural/efeitos adversos , Fatores de Crescimento Neural/líquido cefalorraquidiano , Proteínas S100/efeitos adversos , Proteínas S100/líquido cefalorraquidiano , Adulto , Idoso , Doença de Alzheimer/patologia , Atrofia , Demência/líquido cefalorraquidiano , Ensaio de Imunoadsorção Enzimática , Feminino , Lobo Frontal/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Crescimento Neural/metabolismo , Doenças do Sistema Nervoso/líquido cefalorraquidiano , Lobo Parietal/patologia , Subunidade beta da Proteína Ligante de Cálcio S100 , Proteínas S100/metabolismoRESUMO
In patients with partial craniospinal blocks, the impedance responses to certain functional tests were by 20-30% less obvious. Osteopathic procedures normalised the impedance fluctuations. The data obtained suggest that the CSF dynamics plays an important role in genesis and changes of the head impedance.
Assuntos
Líquido Cefalorraquidiano/fisiologia , Cabeça/fisiologia , Periodicidade , Adulto , Conversão Análogo-Digital , Impedância Elétrica , Humanos , Manipulação Ortopédica , Doenças do Sistema Nervoso/líquido cefalorraquidiano , Doenças do Sistema Nervoso/fisiopatologia , Doenças do Sistema Nervoso/terapia , Pletismografia de Impedância/instrumentação , Processamento de Sinais Assistido por Computador/instrumentaçãoRESUMO
Magnesium is an essential cofactor for many enzymatic reactions, especially those involved in energy metabolism. Deficits of magnesium are prevalent due to inadequate intake or malabsorption and due to the renal loss of magnesium that occurs in certain disease states (alcoholism, diabetes) and with drug therapy (diuretics, aminoglycosides, cisplatin, digoxin, cyclosporin, amphotericin B). Protracted deficits of magnesium in humans and animals result in neurological disturbances, including hyperexcitability, convulsions and various psychiatric symptoms ranging from apathy to psychosis, some of which can be reversed with magnesium supplementation, others requiring correction of the dysregulation mechanism. Although the role of magnesium in neuronal function is not completely understood, a lowering of CSF or brain magnesium can induce epileptiform activity and there is an association between decreased CSF magnesium and the development of seizures. CSF concentrations of magnesium are normally higher than magnesium plasma ultrafiltrate (diffusible) concentrations due to the active transport of magnesium across the blood-brain barrier. Under conditions of magnesium deficiency, CSF concentrations decline, although this decline lags behind and is less pronounced than the changes observed in plasma magnesium concentrations. Decreases in CSF magnesium concentrations correlate with the alterations observed in extracellular brain magnesium concentrations in animals following the dietary deprivation of magnesium. CSF magnesium concentrations can readily be repleted following magnesium supplementation, although high dose magnesium therapy, such as that used in the treatment of convulsions in eclampsia, will only increase CSF magnesium concentrations to a very limited degree (approximately 11-18 per cent) above physiological concentrations. Greater increases in CSF magnesium may occur in neonates since neonatal swine, following treatment with magnesium, have CSF magnesium concentrations that are similar to their plasma concentrations. There has been a recent resurgence of interest in magnesium deficiency and its neurological consequences due to the finding that magnesium, at physiological concentrations, blocks N-methyl-D-aspartate (NMDA) receptors in neurones. NMDA receptors are normally activated by glutamate and/or aspartate which represent the principal neurotransmitters for excitatory synaptic transmission in vertebrate CNS. Magnesium deficiency produces epileptiform activity in the CNS which can be blocked by NMDA receptor antagonists. Other mechanisms, including alterations in Na+/K(+)-ATPase activity, cAMP/cGMP concentrations and calcium currents in pre- and postsynaptic membranes, may also be at least partially responsible for the neuronal effects associated with low brain magnesium. Further studies are necessary to increase our understanding of the neurological implications of magnesium deficit in the central nervous system.
Assuntos
Química Encefálica/fisiologia , Deficiência de Magnésio/metabolismo , Magnésio/metabolismo , Doenças do Sistema Nervoso/metabolismo , Animais , Humanos , Magnésio/líquido cefalorraquidiano , Deficiência de Magnésio/líquido cefalorraquidiano , Deficiência de Magnésio/fisiopatologia , Doenças do Sistema Nervoso/líquido cefalorraquidiano , Doenças do Sistema Nervoso/fisiopatologiaRESUMO
Twelve patients were treated with high-dose intravenous penicillin for neurologic abnormalities of Lyme disease. Headache, stiff neck, and radicular pain usually began to subside by the second day of therapy and were often gone by 7 to 10 days. Five of the 12 patients continued to have intermittent mild headache for several more weeks, but no patient relapsed after therapy was stopped. Compared to 15 previous patients treated with prednisone alone, the duration of meningitic syndrome was significantly shorter in those given penicillin (mean duration, 1 versus 29 weeks, p less than 0.000001). However, in both groups, a mean of 7 to 8 weeks was required for complete recovery of motor deficits. Despite antibiotic therapy, 3 of the 12 patients treated with penicillin continued to have frequent arthralgias, musculoskeletal pain, and fatigue. We conclude that high-dose intravenous penicillin is effective therapy for neurologic abnormalities of Lyme disease.